CytomX Therapeutics (CTMX)
(Delayed Data from NSDQ)
$1.45 USD
+0.07 (5.07%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $1.45 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth D Momentum C VGM
Brokerage Reports
0 items in cart
CytomX Therapeutics, Inc. [CTMX]
Reports for Purchase
Showing records 61 - 80 ( 152 total )
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q1 Financials; Key Data Updates for CX-2009 Ahead in 2H:21
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q4 Financials; Lead PDCs in Ph 2s; Two More Assets into Clinic in 2021
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Year-End 2020 Financials Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q3 Financials; ?2029 Cohorts Kickoff; ?2009 Study Redesigned
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Initial CX-2009 and CX-2029 Phase 2 Data Expected in Late 2021; 3Q20 Financials Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q2 Financials; Expansion Cohorts Should Expand Value
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
ASCO 2020 Takeaways: CX-2029 and CX-2009 Show Positive Progress
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
AACR II 2020 Abstract Roundup for Covered Companies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
ASCO Abstracts Raise More Questions Than Answers; Lowering PT to $12
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
All Eyes on ASCO Presentations; 1Q20 Financials Reported; Raising PT to $16
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q1 Financials; ASCO Data Updates Ahead for Key Programs
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R